David R. Bauer

Davis Polk advised the underwriters in connection with the $345 million public offering of ordinary shares of Horizon Pharma plc. Horizon’s ordinary shares are listed on the NASDAQ Global…

Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering of €7 billion aggregate principal amount of notes by Medtronic Global…

Davis Polk is advising Roche on its approximately $4.3 billion acquisition of Spark Therapeutics, Inc. The transaction, which is expected to be completed in the second quarter of 2019, has…

Davis Polk advised the joint book-running managers in connection with a $4.5 billion registered offering by Eli Lilly and Company of $1.15 billion aggregate principal amount of its 3.375%…

Davis Polk advised the joint book-running managers in connection with a $60 million SEC-registered common stock and pre-funded warrants offering by Aeglea BioTherapeutics, Inc. The common…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 10,222,222 shares of common stock of…

Davis Polk advised the sole initial purchaser in connection with a Rule 144A offering by The Medicines Company of $150 million aggregate principal amount of 3.50% convertible senior…

Davis Polk is advising Mereo BioPharma Group plc on its combination with OncoMed Pharmaceuticals, Inc. The transaction, which is subject to customary closing conditions and the approval of…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the approximately $225 million initial public offering by Orchard Therapeutics…

Davis Polk is advising Novo Nordisk on its $145 million acquisition of the U.S. and Canadian rights to Macrilen from Strongbridge Biopharma Plc. Novo Nordisk will also acquire newly issued…